Dow Up0.35% Nasdaq Up0.02%

Flamel Technologies SA (FLML)

14.42 Down 0.02(0.14%) 2:52PM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
Flamel Technologies SA
Parc Club du Moulin
33, avenue du Docteur Georges Levy
V, 69693
France - Map
Phone: 33 472 78 34 34
Fax: 33 472 78 34 35

Index Membership:N/A
Industry:Drug Delivery
Full Time Employees:N/A

Business Summary 

Flamel Technologies SA, a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary polymer based technology. The company owns and develops drug delivery platforms, such as Micropump that allows generating and marketing modified and/or controlled release of solid and oral dosage formulations of drugs; and LiquiTime, which develops modified/controlled release of liquid formulations for patients having issues swallowing tablets or capsules. Its drug delivery platforms also comprise Trigger Lock that develops tamper-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, which develops extended/modified release of injectable dosage formulations of drugs. The company’s lead products include Bloxiverz, a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Coreg CR, a non-selective antagonist of Beta 1, Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors used for the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction. It has collaborations with various pharmaceutical and biotechnology companies, including GlaxoSmithKline plc. Flamel Technologies SA was founded in 1990 and is headquartered in Vénissieux, France.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Flamel Technologies SA

Key Executives 
Mr. Michael S. Anderson ,
Chief Exec. Officer and Director
Mrs. Sian Crouzet ,
Principal Financial Officer and Financial Controller
Mr. Phillandas T. Thompson ,
Sr. VP and Gen. Counsel
Mr. Steven A. Lisi ,
Sr. VP of Bus. and Corp. Devel.
Mr. Christian Kalita Pharm.D,
Chief Pharmacist and Director of Quality Assurance & Regulatory Affairs
Amounts are as of Dec 31, 2005 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.